Research blog
May 11, 2026 Research use only

TB-500 Research Notes

Selected PubMed sources, evidence limits, and current BioPep USA catalog and documentation status for TB-500. Research use only.

Thymosin beta 4 2D compound structure
Research-use-only scope: This article organizes published sources and BioPep USA records. It does not provide preparation, dosing, injection, human-use, animal-use, therapeutic, diagnostic, cosmetic, or clinical guidance.

TB-500 is described in analytical literature as a synthetic version of an active region of thymosin beta-4. Other selected papers study thymosin beta-4 biology rather than the commercial item.

Questions covered by the selected literature

  • How analytical methods identify TB-500
  • What thymosin beta-4 cell-motility experiments measured
  • Why full-length thymosin beta-4 studies are not interchangeable with TB-500

Evidence limits

Only one selected record is specifically about TB-500 detection. The thymosin beta-4 papers provide component context and do not validate the BioPep USA product.

A paper should be read according to its own model, methods, controls, and endpoints. Cell, animal, analytical, review, and human records are not interchangeable.

Selected PubMed sources

  1. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.. J Chromatogr A. 2012 Nov 23. PMID: 23084823.
  2. Local photorelease of caged thymosin beta4 in locomoting keratocytes causes cell turning.. J Cell Biol. 2001 May 28. PMID: 11381088.
  3. Regulation of PTEN/Akt pathway enhances cardiomyogenesis and attenuates adverse left ventricular remodeling following thymosin β4 Overexpressing embryonic stem cell transplantation in the infarcted heart.. PLoS One. 2013. PMID: 24086577.

BioPep USA record

BioPep USA currently lists TB-500. Use the product page for current options and the documentation page for lot records.

Last reviewed: July 20, 2026.